Innovator Launches First Dual Directional ETFs with Quarterly Outcome Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Source: Globenewswire
- Innovative Product Launch: Innovator Capital Management has introduced the industry's first Dual Directional ETFs, designed to provide investors with the potential for positive returns in both rising and declining markets, thereby enhancing investment flexibility.
- Quarterly Outcome Periods: The new ETFs feature 3-month outcome periods, which not only improve adaptability to market changes but also potentially mitigate timing risks associated with longer outcome periods, addressing investors' needs for dynamic risk management.
- Market Leadership: Since launching the first Buffer ETF in 2018, Innovator has established itself as a leader in Defined Outcome ETFs, currently managing over $309 billion in assets, showcasing its significant influence in the risk-managed investment space.
- Transparency and Liquidity: The ETF structure offers daily liquidity and full pricing transparency, ensuring that investors can effectively manage risks while pursuing returns, further solidifying Innovator's competitive edge in the market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like INN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on INN
Wall Street analysts forecast INN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INN is 4.75 USD with a low forecast of 4.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 4.460
Low
4.50
Averages
4.75
High
5.00
Current: 4.460
Low
4.50
Averages
4.75
High
5.00
About INN
Summit Hotel Properties, Inc. is a real estate investment trust. The Company is focused on owning premium-branded lodging facilities with operating models primarily in the upscale segment of the lodging industry. Its portfolio consists of over 95 assets, 52 of which are wholly owned, with a total of 14,347 guestrooms located in 24 states. Its lodging properties are located in markets with multiple demand generators, such as corporate offices and headquarters, retail centers, airports, state capitols, convention centers, universities, and leisure attractions. Its guestrooms operate under franchise brands owned by Marriott International, Inc. (Marriott), Hilton Worldwide (Hilton), Hyatt Hotels Corporation (Hyatt), and InterContinental Hotels Group (IHG). It holds both general and limited partnership interests in Summit Hotel OP, LP (the Operating Partnership). Substantially, all of its assets are held by, and all of its operations are conducted through, the Operating Partnership.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innocan Pharma Anticipates NYSE Listing with Concurrent Offering
- Listing Plans: Innocan Pharma anticipates listing on NYSE American around January 30, 2026, contingent upon approval of its application and compliance with exchange rules, which will provide the company with broader access to capital markets.
- Concurrent Offering: The company is conducting a concurrent offering of its securities, with details to be disclosed through filings with the SEC and SEDAR+, expected to enhance the company's liquidity and market recognition.
- Trading Transition: Following the NYSE listing, trading of Innocan's common shares on OTCQB will terminate around January 29, 2026, a transition that is expected to improve the company's image and liquidity among investors.
- Business Development: Innocan's innovations in pharmaceuticals and wellness, particularly its CBD-loaded liposome drug delivery platform, are anticipated to further drive market share growth by addressing the demand for non-opioid pain management solutions.
Continue Reading
Summit Hotel Properties (INN) Declares $0.08 Cash Dividend with 6.6% Annual Yield
- Dividend Announcement: Summit Hotel Properties has declared a cash dividend of $0.08 per share for Q4 2025, reflecting a 6.6% annualized yield based on the closing price on January 21, 2026, indicating the company's strong cash flow and commitment to shareholder returns.
- Preferred Stock Dividends: The company will also pay a dividend of $0.390625 per share for its 6.25% Series E Preferred Stock and $0.3671875 for its 5.875% Series F Preferred Stock, enhancing its appeal to preferred stock investors.
- Operating Partnership Distribution: Authorized cash distributions include $0.328125 per unit for the 5.25% Series Z Preferred Units, demonstrating the company's flexibility in financing structures and commitment to its investors.
- Portfolio Overview: As of January 22, 2026, Summit Hotel's portfolio consists of 95 properties with 14,348 guestrooms across 24 states, showcasing its strong competitive position and market penetration in the upscale hotel sector.
Continue Reading